In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Background: A limited number of approved therapeutic options are available to metastatic medullary thyroid cancer (MTC) patients, and the response to conventional chemotherapy and/or radiotherapy strategies is inadequate. Sporadic and inherited mutations in the tyrosine kinase RET result in oncogeni...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Bentzien, Frauke, Zuzow, Marcus, Heald, Nathan, Gibson, Anna, Shi, Yongchang, Goon, Leanne, Yu, Peiwen, Engst, Stefan, Zhang, Wentao, Huang, Donghui, Zhao, Lora, Vysotskaia, Valentina, Chu, Felix, Bautista, Rajana, Cancilla, Belinda, Lamb, Peter, Joly, Alison H., Yakes, F. Michael
Format: Artigo
Idioma:Inglês
Publicat: Mary Ann Liebert, Inc. 2013
Matèries:
Thyroid Cancer and Nodules
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868259/
https://ncbi.nlm.nih.gov/pubmed/23705946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2013.0137
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars